Journal of Oncology / 2010 / Article / Fig 3

Research Article

Architectural Heterogeneity in Tumors Caused by Differentiation Alters Intratumoral Drug Distribution and Affects Therapeutic Synergy of Antiangiogenic Organoselenium Compound

Figure 3

(a) Bar graphs show MVD counts per high-power field (HPF) (original magnification, 400 × ) in the untreated versus MSC-treated xenografts and surgical samples following 14 days of MSC treatment (0.2 mg/mouse/day). Significant reduction in MVD was seen in A253 and H69 xenografts after 14 days of MSC treatment with no changes seen in A549 xenografts or the surgical samples. (b) MSC led to an improved vascular maturation in A253, H69, A549 xenografts and PDSCC but did not induce any change in WDSCC and normal liver. (c) Treatment with MSC (0.2 mg/mouse/day × 14) led to a lowering of interstitial fluid pressure in A253 but not in H69 and A549 xenografts. (d) As a consequence, there was a significant improvement in tumor doxorubicin fluorescence intensity gradient in A253 xenografts but not in H69 or A549 xenografts. (e) MSC did not result in an improvement in tumor doxorubicin fluorescence intensity gradient in the surgical samples PDSCC and WDSCC.
396286.fig.003a
(a)
396286.fig.003b
(b)
396286.fig.003c
(c)
396286.fig.003d
(d)
396286.fig.003e
(e)

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at help@hindawi.com to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19.